Polypharmacy, aging, and cancer

ONCOLOGY

Volumn 22, Issue 9, 2008, Pages 1052-1055

  Tam McDevitt, Jennifer ^a  

^a Geriatric Oncology Consortium   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOPLATIN; CETUXIMAB; CYTOCHROME P450; DRUG METABOLIZING ENZYME; HERBACEOUS AGENT; HYPERICUM PERFORATUM EXTRACT; IMATINIB; IRINOTECAN; LAXATIVE; LORATADINE; NEUROLEPTIC AGENT; NON PRESCRIPTION DRUG; OMEPRAZOLE; OPIATE; VASODILATOR AGENT;

AGING; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; COST BENEFIT ANALYSIS; DIET SUPPLEMENTATION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INFORMATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG TREATMENT FAILURE; FINANCIAL MANAGEMENT; GERIATRIC PATIENT; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; KIDNEY FUNCTION; MALIGNANT NEOPLASTIC DISEASE; MEDICAL EDUCATION; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHARMACODYNAMICS; POLYPHARMACY; PRESCRIPTION; PREVENTIVE MEDICINE; RISK BENEFIT ANALYSIS; RISK FACTOR; SELF CARE; TREATMENT RESPONSE;

AGE FACTORS; AGING; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; HUMANS; NEOPLASMS; PATIENT COMPLIANCE; POLYPHARMACY;

EID: 52649173132     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Rollason V, Vogt N: Reduction of polypharmacy in the elderly: A systematic review of the role of the pharmacist. Drugs Aging 20:817-832, 2003.
2. Azad N, Tierney M, Victor G, et al: Adverse drug events in the elderly population admitted to a tertiary care hospital. J Healthc Manag 47:295-305, 2002.
3. Jorgensen T, Johansson S, Kennerfalk A, et al: Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother 35:1004-1009, 2001.
4. Hanlon JT, Fillenbaum GG, Ruby C, et al: Epidemiology of over-the-counter drug use in community dwelling elderly: United States perspective. Drugs Aging 18:123-131, 2001.
5. Yancik R, Ries LA: Aging and cancer in America: Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 14:17-24, 2000.
6. Sokol KC, Knudsen JF, Li MM: Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Therap 32:169-175, 2007.
7. Hume AL: Safe and effective drug therapy in older adults. Med Health R I 88:15-17, 2005.
8. Stern M: Case studies in geriatric emergencies: Polypharmacy. Emerg Med 39:10, 2007.
9. Nahin RL, Fitzpatrick AL, Williamson JD, et al: Use of herbal medicine and other dietary supplements in community-dwelling older people: Baseline data from the Ginkgo Evaluation of Memory Study. J Am Geriatr Soc 54:1725-1735, 2006.
10. Patel KB, Klepser ME, Marangos MN, et al: Drug interactions in the elderly: The role of polypharmacy. Phila Coll Pharm Sci Apr: 19S-26S, 1994.
11. Schainen JS, Burggraf V: Screening for polypharmacy in a nursing home care unit, in Burggraf V, Barry R (eds): Gerontological Nursing: Current Practice and Research, pp 189-193. Thorofare, NJ; Slack; 1996.
12. Corcoran ME: Polypharmacy in the older patient with cancer. Cancer Control 4:419-428, 1997.
13. Wallace K, Cantor A, Overcash J, et al: Influence of concomitant medications on toxicity from chemotherapy in elderly patients: Focus on cytochrome P-450 inhibition and protein binding effects (abstract 8025). J Clin Oncol 23(16S):735s, 2005.
14. Nies AS, Shand DG, Wilkinson GR: Altered hepatic blood flow and drug disposition. Clinical Pharmacokinetics 1:135-155, 1976.
15. Wood AJ, Feely J: Pharmacokinetic drug interactions with propranolol. Clinical Pharmacokinetics 8:253-262, 1983.
16. Mathijssen RHJ, Verweij J, de Bruijn P, et al: Effects of St. John's wort on irinotecan metabolism. JNCI Cancer Spectrum 94:1247-1249, 2002.
17. Mansky PJ, Straus SE: St John's wort: More implications for cancer patients. JNCI Cancer Spectrum 94:1187-1188, 2002.
18. Spina E, Scordo MG: Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging 19:299-320, 2002.
19. Gebhardt MW, Governali JF, Hart EJ: Drug related behavior, knowledge and misconceptions among a selected group of senior citizens. J Drug Educ 8:85-92, 1978.
20. Zhan C, Arispe I, Kelley E, et al: Ambulatory care visits for treating adverse drug effects in the United States, 1995-2001. Joint Commission Journal on Quality of Patient Safety 31:372-378, 2005.
21. Perry DP: When medicine hurts instead of helps. Consultant Pharmacist 14:1326-1330, 1999.
22. Bootman JL, Harrison DL, Cox E: The health care cost of drug-related morbidity and mortality in nursing facilities. Arch Intern Med 157:2089-2096, 1997.
23. Scharlach AE, Mor-Barak ME, Katz A, et al: Generation: A corporate-sponsored retiree health care program. Gerontologist 32:265-269, 1992.
24. Colt HG, Shapiro AP: Drug induced illness as a cause for admission to a community hospital. J Am Geriatr Soc 37:323-326, 1989.
25. Beers MH: Explicit criteria for determining potentially inappropriate medications use by the elderly, an update. Arch Intern Med 157:1531-1536, 1997.